Johnson & Johnson $JNJ Shares Bought by Sienna Gestion

Key Points

• Sienna Gestion increased its stake in Johnson & Johnson by 9.3% in Q3 to 142,127 shares (about $24.03 million), making JNJ its 9th-largest holding and 1.7% of the firm's assets.
• Insiders have recently sold significant stock—EVPs Vanessa Broadhurst and Timothy Schmid sold 6,197 and 22,623 shares respectively—and insiders have offloaded 30,142 shares in the last 90 days valued at $7.36 million; insiders now own 0.16% of JNJ.
• Johnson & Johnson declared a $1.30 quarterly dividend (ex-dividend Feb 24, payable Mar 10; ~2.2% yield) and reported quarterly results of $2.46 EPS on $24.28 billion in revenue; the stock holds a consensus "Moderate Buy" rating with an average target of $234.87.

Sienna Gestion grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 9.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 142,127 shares of the company's stock after purchasing an additional 12,073 shares during the period. Johnson & Johnson makes up 1.7% of Sienna Gestion's holdings, making the stock its 9th largest position. Sienna Gestion's holdings in Johnson & Johnson were worth $24,027,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of JNJ. SOA Wealth Advisors LLC. lifted its stake in Johnson & Johnson by 0.7% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company's stock valued at $1,371,000 after acquiring an additional 53 shares during the period. Ethos Financial Group LLC increased its stake in shares of Johnson & Johnson by 0.6% in the third quarter. Ethos Financial Group LLC now owns 9,110 shares of the company's stock worth $1,689,000 after acquiring an additional 53 shares during the period. Pinnacle Holdings LLC raised its holdings in shares of Johnson & Johnson by 0.5% during the third quarter. Pinnacle Holdings LLC now owns 11,214 shares of the company's stock worth $2,079,000 after purchasing an additional 54 shares during the last quarter. Bouchey Financial Group Ltd lifted its position in Johnson & Johnson by 0.8% during the third quarter. Bouchey Financial Group Ltd now owns 7,249 shares of the company's stock valued at $1,344,000 after purchasing an additional 54 shares during the period. Finally, Heritage Oak Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 3.5% in the third quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company's stock valued at $304,000 after purchasing an additional 55 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Activity

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares of the company's stock, valued at $6,540,469.77. The trade was a 45.80% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 0.4%

Johnson & Johnson stock opened at $240.57 on Monday. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71. The stock has a market capitalization of $579.75 billion, a PE ratio of 21.77, a price-to-earnings-growth ratio of 2.37 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The business has a 50 day simple moving average of $228.36 and a 200-day simple moving average of $204.37.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. Johnson & Johnson's payout ratio is currently 47.06%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on JNJ. Royal Bank Of Canada lifted their price objective on Johnson & Johnson from $240.00 to $255.00 and gave the company an "outperform" rating in a research note on Tuesday, February 3rd. Morgan Stanley set a $262.00 target price on Johnson & Johnson and gave the stock an "overweight" rating in a report on Wednesday, January 28th. TD Cowen lifted their price target on Johnson & Johnson from $222.00 to $250.00 and gave the company a "buy" rating in a research report on Thursday, January 22nd. Freedom Capital lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 16th. Finally, Daiwa Securities Group raised their price objective on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an "outperform" rating in a research note on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $234.87.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.